ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
THE DEA And ACCESS TO TRT TELEMEDICINE
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Blackhawk" data-source="post: 249162" data-attributes="member: 16042"><p>Yes, I just think it unlikely to attract enough patients to take the effort. The opening blurb:</p><p></p><p><em>"The DEA has proposed new rules to update the Ryan Haight Act, which could negatively affect telemedicine prescribing of non-narcotic medications in Schedules III, IV, and V. Testosterone is considered a Schedule III medication.</em></p><p><em></em></p><p><em>These rules would require in-person evaluations (physical exams), stricter record-keeping, increased coordination between physicians, and more frequent smaller refills. If approved, the update would go into effect after the current DEA waiver of the in-person exam requirement expires on May 11, 2023.</em></p><p><em></em></p><p><em>This could create unnecessary burdens for both patients and doctors, leading to limited access to treatment and increased risk of harm to patients. "</em></p><p></p><p>Then at the end:</p><p></p><p><em>"Your Defy Medical team is continuing to monitor industry changes, and we are prepared to adapt to any regulatory updates. We will communicate clearly with patients as this situation evolves."</em></p><p></p><p>OK then sounds like no big deal, they have me covered.</p><p></p><p>People are lazy. All of this is stated in a mild mannered tone. I am surprised there is not a bit more urgency or intensity in how they presented this.</p><p></p><p>The suggested response comment is also mild and includes very little rebuttal substance.</p></blockquote><p></p>
[QUOTE="Blackhawk, post: 249162, member: 16042"] Yes, I just think it unlikely to attract enough patients to take the effort. The opening blurb: [I]"The DEA has proposed new rules to update the Ryan Haight Act, which could negatively affect telemedicine prescribing of non-narcotic medications in Schedules III, IV, and V. Testosterone is considered a Schedule III medication. These rules would require in-person evaluations (physical exams), stricter record-keeping, increased coordination between physicians, and more frequent smaller refills. If approved, the update would go into effect after the current DEA waiver of the in-person exam requirement expires on May 11, 2023. This could create unnecessary burdens for both patients and doctors, leading to limited access to treatment and increased risk of harm to patients. "[/I] Then at the end: [I]"Your Defy Medical team is continuing to monitor industry changes, and we are prepared to adapt to any regulatory updates. We will communicate clearly with patients as this situation evolves."[/I] OK then sounds like no big deal, they have me covered. People are lazy. All of this is stated in a mild mannered tone. I am surprised there is not a bit more urgency or intensity in how they presented this. The suggested response comment is also mild and includes very little rebuttal substance. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
THE DEA And ACCESS TO TRT TELEMEDICINE
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top